Please login to the form below

Not currently logged in
Email:
Password:

Astellas' EMEA president Ken Jones resigns

He will be succeeded by the firm's marketing head Yukio Matsui

Astellas Ken Jones

He joined Yamanouchi as vice president, European marketing, in 2003 ahead of its 2005 merger with Fujisawa to form Astellas, and prior that spent 16 years at Allergan working in Europe, the US and Japan.

Jones' replacement at Astellas will be Yukio Matsui, who currently serves as senior vice president, head of marketing strategy for Astellas' global strategic products.

Yoshihiko Hatanaka, Astellas' president and CEO, said: “The appointment of Yukio Matsui as president of EMEA Operations brings more than 30 years experience to the role - including various important positions in all four regions including Japan, Americas, EMEA, and Asia/Oceania.

“This experience will be crucial in securing the future success of Astellas for all stakeholders and helping the organisation to stay focused on our vision to be on the forefront of healthcare change to turn innovative science into value for patients." 

During his time at Astellas Matsui has held a variety of sales, marketing and strategic planning roles and will start in his new role on 1 April.

He said: "I join at an exciting time with recent launches of a number of innovative medicines and a compelling pipeline in late-stage clinical development for our region.

“With my international business experiences in both developed countries as well as emerging countries and the combined talents of more than 4,700 colleagues across all the functions in the EMEA region, I am confident we will deliver on the Astellas promise of improving the lives of those patients who depend on our medicines."

7th March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics